Abstract
Efficient therapeutic protein delivery is a challenging task in several disease contexts and particularly when the CNS is concerned. Different approaches for brain-directed delivery have been thus far investigated, including direct injection of molecules or of their coding information carried by dedicated vector systems within the brain parenchyma or in the ventricular space, intravenous systemic administration of molecules/vectors modified to target and cross the blood-brainbarrier, and exploitation of allogeneic and/or autologous and genetically modified cells as vehicles for the therapeutic of interest. Among these, we here review one of the most promising approaches based on hematopoietic stem cells, taking advantage of lysosomal storage disorders as representative disease setting.
Keywords: Hematopoietic stem cells, gene therapy, central nervous system, lysosomal storage disorders, blood-brain-barrier, protein delivery, brain parenchyma, ventricular space
Current Gene Therapy
Title:Genetically-Modified Hematopoietic Stem Cells and their Progeny for Widespread and Efficient Protein Delivery to Diseased Sites: The Case of Lysosomal Storage Disorders
Volume: 12 Issue: 5
Author(s): Alessandra Biffi
Affiliation:
Keywords: Hematopoietic stem cells, gene therapy, central nervous system, lysosomal storage disorders, blood-brain-barrier, protein delivery, brain parenchyma, ventricular space
Abstract: Efficient therapeutic protein delivery is a challenging task in several disease contexts and particularly when the CNS is concerned. Different approaches for brain-directed delivery have been thus far investigated, including direct injection of molecules or of their coding information carried by dedicated vector systems within the brain parenchyma or in the ventricular space, intravenous systemic administration of molecules/vectors modified to target and cross the blood-brainbarrier, and exploitation of allogeneic and/or autologous and genetically modified cells as vehicles for the therapeutic of interest. Among these, we here review one of the most promising approaches based on hematopoietic stem cells, taking advantage of lysosomal storage disorders as representative disease setting.
Export Options
About this article
Cite this article as:
Biffi Alessandra, Genetically-Modified Hematopoietic Stem Cells and their Progeny for Widespread and Efficient Protein Delivery to Diseased Sites: The Case of Lysosomal Storage Disorders, Current Gene Therapy 2012; 12 (5) . https://dx.doi.org/10.2174/156652312802762572
DOI https://dx.doi.org/10.2174/156652312802762572 |
Print ISSN 1566-5232 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-5631 |
Call for Papers in Thematic Issues
Programmed Cell Death Genes in Oncology: Pioneering Therapeutic and Diagnostic Frontiers (BMS-CGT-2024-HT-45)
Programmed Cell Death (PCD) is recognized as a pivotal biological mechanism with far-reaching effects in the realm of cancer therapy. This complex process encompasses a variety of cell death modalities, including apoptosis, autophagic cell death, pyroptosis, and ferroptosis, each of which contributes to the intricate landscape of cancer development and ...read more
Related Journals
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
New Approaches to Target the Androgen Receptor and STAT3 for Prostate Cancer Treatments
Mini-Reviews in Medicinal Chemistry An Inventory of Short Term and Long Term Changes in Gene Expression Under Interferon β Treatment of Relapsing Remitting MS Patients
Current Pharmaceutical Design Micro- and Nano-particulate Strategies for Antigen Specific Immune Tolerance to Treat Autoimmune Diseases
Pharmaceutical Nanotechnology Glutamate in CNS Neurodegeneration and Cognition and its Regulation by GCPII Inhibition
Current Medicinal Chemistry Neurochemical and Neuropharmacological Aspects of Circadian Disruptions: An Introduction to Asynchronization
Current Neuropharmacology The Role of T-Helper Cells in Atherosclerosis
Cardiovascular & Hematological Agents in Medicinal Chemistry Voltage-Gated Sodium Channel Blockers as Immunomodulators
Recent Patents on CNS Drug Discovery (Discontinued) Gene Therapy and Targeted Toxins for Glioma
Current Gene Therapy PKC-θ is a Drug Target for Prevention of T Cell-Mediated Autoimmunity and Allograft Rejection
Endocrine, Metabolic & Immune Disorders - Drug Targets Activation of the Liver X Receptor Inhibits Th17 and Th1 Responses in Behcet`s Disease and Vogt-Koyanagi-Harada Disease
Current Molecular Medicine The Endocannabinoid System and Multiple Sclerosis
Current Pharmaceutical Design In Vivo DNA Electrotransfer for Immunotherapy of Cancer and Neurodegenerative Diseases
Current Drug Metabolism The Role of HTS in Drug Discovery at the University of Michigan
Combinatorial Chemistry & High Throughput Screening Effects of Erythropoietin on Brain Function
Current Pharmaceutical Biotechnology Myelin Sheaths and Autoimmune Response Induced by Myelin Proteins and Alphaviruses. I. Physicochemical Background
Current Medicinal Chemistry Therapeutic Peptide Mimetics Looking for a Turn to Block Aberrant Players of Malignancy
Current Cancer Therapy Reviews Sex Steroids in Autoimmune Diseases
Current Topics in Medicinal Chemistry The Role of Anaphylatoxins C3a and C5a in Regulating Innate and Adaptive Immune Responses
Inflammation & Allergy - Drug Targets (Discontinued) Genetic and Molecular Basis of QTL of Diabetes in Mouse: Genes and Polymorphisms
Current Genomics Induction of Regulatory T Cells by Dendritic Cells through Indoleamine 2,3- dioxygenase: A Potent Mechanism of Acquired Peripheral Tolerance
Current Medicinal Chemistry